Validating Urinary Chemokines to Detect Rejection
Author Information
Author(s): Ilaria Gandolfini, Benedetta Mordà, Elena Martinelli, Marco Delsante, Giovanni Maria Rossi, Micaela Gentile, Sara Alibrandi, Daniel Salvetti, Omar Ben Youssif, Enrico Fiaccadori, Alessandra Palmisano, Paolo Cravedi, Umberto Maggiore
Primary Institution: University Hospital of Parma, Parma, Italy
Hypothesis
Can urinary chemokines CXCL9 and CXCL10 be used to noninvasively rule out acute rejection in kidney transplant recipients?
Conclusion
The study supports the use of a urinary chemokine-based model to identify kidney transplant patients at low risk of acute rejection, allowing them to safely avoid biopsies.
Supporting Evidence
- The model has a high diagnostic discriminatory value for detecting acute rejection with an ROC AUC of 81.3%.
- Implementing this model could allow avoiding 59% of biopsies in low-risk patients.
- The study validated the model in an independent cohort, confirming its utility.
Takeaway
Doctors can use a urine test to tell if kidney transplant patients need a biopsy, which is a big deal because biopsies can be uncomfortable.
Methodology
The study validated a predictive model for acute rejection using urinary chemokines in kidney transplant recipients who underwent biopsies.
Potential Biases
Inter-laboratory variability in measurements may affect the predictive performance of the model.
Limitations
The validation was conducted on a limited number of subjects compared to the original cohort.
Participant Demographics
Participants were kidney transplant recipients aged 48.5 ± 12.7 years, with 62.1% males and 10.5% receiving living donations.
Statistical Information
P-Value
0.045
Confidence Interval
69.1 to 93.2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website